Vivo Bio Tech Ltd.

Your Drug Discovery Partner

Date: 12/08/2015

To
Deputy Manager
Dept. of Corporate Services,
Bombay Stock Exchange Limited
P J Towers, Dalal Street,
Fort, MUMBAI – 400001

Sub: Outcome of Board Meeting held on 12th August 2015-Reg.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 12th August 2015 and transacted following business:

1. Approved the Unaudited Financial Results for Quarter ending on 30th June 2015

We are herewith attaching the results sheet and Limited Review Report for quarter ended 30th June 2015 pursuant to Clause 41 of Listing agreement.

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

M Kalyan Ram


Whole Time Director

Vivo Bio Tech Ltd.

Your Drug Discovery Partner

Rs. In Lakhs

Unaudit	ed Financial Results for the quarter ended on 30/06/2015			T	
	4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		NIADTED ENG		
S.No.	PARTICULARS		QUARTER END 30.06.2015 31.03.2015		YEAR ENDED
		Unaudited			31.03.2015
	1 Income from Operations	Unaudited	Audited	Unaudited	Audited
	a) Net Sales/ Income from Operations	505.00	2:		
	b) Other Operating Income	605.22		366.64	1778.8
	Total Income from operations	0.00	5.00	0.00	0.0
	2 Expenses	605.22	598.38	366.64	1778.8
	a. Increase/(decrease) in stock in trade and WIP				
	b. Consumption of Raw materials	0.00	123.00	0.00	-438.0
	c. Purchase of traded goods	190.08	510.93	70.92	745.0
	d. Employees Cost	0.00	0.00	0.00	0.0
	e. Depreciation	88.08	81.41	54.60	293.7
	f. Other Expenditure	76.16	174.55	41.56	304.6
	1.Administrative Expenditure				
	g. Total	210.79	259.73	225.00	897.5
	Profit/loss from Operations before other income, finance cost	565.11	602.83	392.09	1802.9
3	and exceptions items(1-2)				
	Other income	40.11	-4.45	-25.45	-24.0
	Profit/(loss) from Ordinary activities before finance costs and	17.89	31.87	22.50	94.7:
5	exceptional items(3+4)				
	Finance costs	58.00	27.43	-2.95	70.67
		9.60	19.16	10.15	51.40
7	Profit/(loss) from Ordinary activities after finance costs but		-		
,	before exceptional items(5-6) Exceptional items	48.40	8.27	-13.10	19.2
		*	0.00	0.00	0.00
10	Profit/Loss from Ordinary Activities before tax(7-8) Tax Expense	48.40	8.27	-13.10	19,27
		14.52	-32.91	0.00	-27.01
12	Net Profit/Loss from Ordinary Activities after Tax(9-10)	33.88	41.18	-13.10	46.28
12	Extraordinary Items (Net of Tax expense of RsLakh)	*	0.00	0.00	0.00
14	Net Profit/Loss for the Period(11-12)	33.88	41.18	-13.10	46.28
14	Paid Up Share Capital(Face Value of Rs.10/-each)	935.05	935.05	935.05	935.05
15	Reserves Excluding Revaluation Reserves as per Balance sheet of				333.03
	previous accouting year	0.00	0.00	0.00	0.00
j	Earning Per Share(EPS)(Before Extraordinary items)		5.00	0.00	0.00
_	a)Basic	0.36	0.44	-0.14	0.49
	b)Diluted	0.36	0.44	-0.14	
.ii	Earning Per Share(EPS)(After Extraordinary items)	1.00	0.44	-0.14	0.49
	a) Basic	0.36	0.44	-0.14	0.40
	b) Diluted	0.36	0.44	-0.14	0.49



Vivo Bio Tech Ltd.

Your Drug Discovery Partner

PART -	II- Select Information for the Qtr and year ended on 31/03/2015				
Α	Particulars of Shareholding				
	1 Public Shareholding				
	Number of Shares	3043970	3043970	2926437	3043970
	Percentage of Shareholding	32.55%	32.55%	31.30%	32.55%
	2 Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered	0.00	0.00	0.00	0.00
	:Number of Shares				0.00
	:Percentage of Shares	0.00	0.00	0.00	0.00
	(as a % of the total shareholding of promoter and Promoter Gr	oup)		0.00	
	: Percentage of Shares	0.00	0.00	0.00	0.00
	(as a % of the total sharecapital of the company)	0.00	0.00	0.00	0.00
	b) Non-Encumbered				
	:Number of Shares	6306550	6306550	6424083	6306550
	:Percentage of Shares	100%	100%	100%	100%
	(as a % of the total shareholding of promoter and Promoter Gr	oup)			
	: Percentage of Shares	67.45%	67.45%	68.70%	67.45%
	(as a % of the total sharecapital of the company)				

Notes

The above results were reviwed by the Audit committee and approved by the Board of Directors in their meeting held on

- 1 12th August, 2015
- 2 Financials are prepared in accordance with generally accepted accounting principles and accounting standards Figures of previous year/ period have been regrouped and reclassified or recast or re-arranged where ever considered
- 3 necessary
- 4 Status of complaints from the investors during the quarter ended 30th June, 2015 Pending- 0 Nos Complaints Received -3 Nos., Complaints resolved - 3 Nos., Complaints lying unresolved - 0 No.
- 5 The company Operates in Only one Segment


Place: Hyderabad

Date: 12th August 2015

For Vivo Bio Tech Limited

M Kalyan Ram Whole Time Director DIN: 02012580

men



Tel. : (91-40) 2332 6666, 2331 2554

332 0000, 2331 2334

2339 3967, 2332 1470

Fax : (9 E-mail : pr

: (91-40) 2339 2474 | : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

To,
The Board of Directors,
M/s. VIVO BIO TECH LIMITED
Hyderabad

Limited Review Report for the quarter ended 30th June 2015

We have reviewed the accompanying statement of unaudited financial results of M/s. VIVO BIO TECH LIMITED for the quarter ended 30th June, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards Specified under Section 133 of the Companies Act 2013 and Rule 7 of the Companies (Accounts) Rules 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P Murali & Co.
Chartered Accountants

Partner

Place: Hyderabad

Date: 12th August, 2015